Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus

International Journal of Gynecological Pathology

Volumn 24, Issue 2, 2005, Pages 118-124

  Longatto Filho, Adhemar ^a,b   Utagawa, Maria Lúcia ^a   Kasumi Shirata, Neuza ^a   Miranda Pereira, Sônia Maria ^a   Namiyama, Gislene M ^c   Takami Kanamura, Cristina ^a   Da Cunha Santos, Gilda ^c   Almeida De Oliveira, Marilene ^c   Wakamatsu, Alda ^a   Nonogaki, Suely ^a   Roteli Martins, Cecília ^d   Di Loreto, Celso ^a   Mattosinho De Castro Ferraz, Maria Da Gloria ^c   Sakamoto Maeda, Marina Yoshiê ^a   Alves, Venâncio A F ^e   Syrjänen, Kari ^f  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b UNIVERSITY OF MINHO   (Portugal)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL MATERNIDADE LEONOR MENDES DE BARROS   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cervical cancer; Human papillomavirus; Ki67; Liquid based cytology; p16

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; PROTEIN P16INK4A; TUMOR MARKER;

ADULT; ARTICLE; BRAZIL; CANCER GRADING; CANCER SCREENING; COLPOSCOPY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; BIOSYNTHESIS; COMPARATIVE STUDY; IMMUNOHISTOCHEMISTRY; METABOLISM; PAPILLOMA VIRUS; PRECANCER; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY; VIRUS INFECTION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 20144377080     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RCT.0000157092.44680.25     Document Type: Article

References (30)

1. Monsonego J, Bosch FX, Coursaget P, et al. Cervical cancer control, priorities and new directions. Int J Cancer 2004;108:329-33.
2. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55: 244-65.
3. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
5. INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix. Int J Cancer 2001;92:276-84.
6. Santos M, Montagut C, Mellado B, et al. Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol 2004;23:206-14.
7. Lu DW, El-Mofty SK, Wang HL. Expression of p16 and p53 in squamous cell carcinomas of the anorectal region harbouring human papillomavirus DNA. Mod Pathol 2003;16:692-9.
8. Ferreux E, Lont AP, Horenblas S, et al. Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol 2003;201:109-18.
9. Fregonezi PA, Teresa DB, Duarte RA, et al. P16 (INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem 2003;51:1291-7.
10. Schorge JO, Lea JS, Elias KJ, et al. P16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol 2004;190:668-73.
11. Zielinski GD, Snijders PJF, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16INK4A expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-43.
12. Alfsen GC, Reed W, Sandstad B, et al. The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinoma os the cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma. Cancer 2003;98:1880-9.
13. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004;28:160-7.
14. Kruse AJ, Skaland I, Janssen EA, et al. Quantitative molecular parameters to identify low-risk and high risk early lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol 2004;23:100-9.
15. Maeda MYS, Simões M, Wakamatsu A, et al. Relevance of the rates of PCNA, Ki-67 and p53 expression according to the epithelial compartment in cervical lesions. Pathologica 2001;93:189-95.
16. de Putte GV, Kristensen GB, Lie K, et al. Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol 2004;92:40-6.
17. Arbyn M, Buntinx F, Ranst MV, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93.
18. INK4A and early endocervical glandular neoplasia. Hum Pathol 2002;33:899-904.
19. Sahebali S, Depuydt CE, Segers K, et al. Ki-67 immunohistochemistry in liquid-based cervical cytology: useful as an adjunctive tool? J Clin Pathol 2003;56:681-6.
20. Akpolat I, Smith DA, Ramzy I, et al. The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material. Cancer Cytopathol 2004;102:42-9.
21. INK4A as an adjunct test in liquid-based cytology. Anal Quant Cytol Histol 2003;25:8-11.
22. Nonogaki S, Wakamatsu A, Longatto Filho A, et al. Hybrid Capture II and Polymerase Chain Reaction for Identifying HPV Infections in samples collected in a new collection medium: A comparison. Acta Cytol 2004;48:514-20.
23. Solomon D, Davey D, Kurman R, et al. N. The 2001 Bethesda System Terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
24. Howard M, Sellers J, Kaczorowski J, et al. Optimal cutoff of the hybrid capture II human papillomavirus test for self-collected vaginal, vulvar, and urine specimens in a colposcopy referral population. J Low Genital Tract Dis 2004;8:33-7.
25. Evangelou K, Bramis J, Peros I, et al. Electron microscopy evidence that cytoplasmic localization of the p16 (INK4A) "nuclear cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem 2004;79:5-10.
26. INK4A as a marker for cervical dyskeratosis: CIN and cGIN in cervical biopsies and Thin-Prep™ smears. J Clin Pathol 2003;56:56-63.
27. INK4A in liquid-based specimens (SurePath™) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 2002;27:365-70.
28. Akpolat I, Smith DA, Ramzy I, et al. The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material. Cancer Cytopathol 2004;102:42-9.
29. Sahebali S, Depuydt CE, Segers K, et al. p16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer 2004;108: 871-6.
30. Kruse AJ, Baak JP, Janssen EA, et al. Low- and high-risk CIN1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables. J Pathol 2003;199:462-70.